RT Journal Article
SR Electronic
T1 Breakthrough SARS-CoV-2 infections in MS patients on disease modifying therapies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.22.22269630
DO 10.1101/2022.01.22.22269630
A1 Schiavetti, Irene
A1 Cordioli, Cinzia
A1 Stromillo, Maria Laura
A1 Ferrò, Maria Teresa
A1 Laroni, Alice
A1 Cocco, Eleonora
A1 Cola, Gaia
A1 Pasquali, Livia
A1 Rilla, Maria Teresa
A1 Signoriello, Elisabetta
A1 Iodice, Rosa
A1 Sapio, Alessia Di
A1 Lanzillo, Roberta
A1 Caleri, Francesca
A1 Annovazzi, Pietro
A1 Conte, Antonella
A1 Liberatore, Giuseppe
A1 Ruscica, Francesca
A1 Docimo, Renato
A1 Bonavita, Simona
A1 Ulivelli, Monica
A1 Cavalla, Paola
A1 Patti, Francesco
A1 Ferraro, Diana
A1 Clerico, Marinella
A1 Immovilli, Paolo
A1 Filippo, Massimiliano Di
A1 Salvetti, Marco
A1 Sormani, Maria Pia
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/01/31/2022.01.22.22269630.abstract
AB Background Patients with Multiple Sclerosis (pwMS) treated with anti-CD20 or fingolimod showed a reduced humoral response to SARS-CoV-2 vaccines. In this study we aimed to monitor the risk of breakthrough SARS-CoV-2 infection in pwMS on different Disease Modifying Therapy (DMT).Methods Data on number of vaccinated patients and of patients with a breakthrough infection were retrospectively collected in 27 Italian MS centers. We estimated the rate of breakthrough infections and of infection requiring hospitalization per DMT.Findings 19641 vaccinated pwMS were included in the database. After a median follow-up of 8 months, we observed 137 breakthrough infections. As compared to the other DMTs, the rate of breakthrough infections was significantly higher on ocrelizumab (0.57% vs 2.00%, RR=3.55,95%CI=2.74-4.58, p<0.001) and fingolimod (0.58% vs 1.62%, RR=2.65,95%CI=1.75-4.00, p<0.001), while there were no significant differences in any other DMT group. In the ocrelizumab group the hospitalization rate was 16.7% vs 19.4% in the pre-vaccination era (RR=0.86,p=0.74) and it was 3.9% in all the other DMT groups vs 11.9% in the pre-vaccination period (RR=0.33,p=0.02).Interpretation The risk of breakthrough SARS-CoV-2 infections is higher in patients treated with ocrelizumab and fingolimod, and the rate of severe infections was significantly reduced in all the DMTs excluding ocrelizumab.Competing Interest StatementAnnovazzi received honoraria for lecturing and participation in advisory boards, and/or travel expenses for attending congresses and meetings from Almirall, Biogen, BMS-Celgene, Merck, Novartis, Roche, Sanofi-Genzyme, Teva Italia, and Viatris. Bonavita received speaker and/or advisors board fee from Biogen, Novartis, Roche, viatris, Merck serono. Caleri received honoraria for advisory board and/or for public speaking, and/or travel grant, from Biogen, Merck, Teva, Novartis, Sanofi-Genzyme, Roche. Cavalla has received advisory board membership, speaker honoraria or travel grants to attend national and international conferences from Biogen, Merck-Serono, Teva, Roche, Novartis, Cellgene-BMS and Sanofi-Genzyme. Clerico received grants and consulting fees from Merck, Biogen, Novartis, Sanofi-Genzyme, Roche, Almirall. Cola, Pasquali, Cocco, Ferro, Liberatore, Rilla, Stromillo have nothing to disclose. Conte reports speaking honoraria from Merck, Sanofi, Novartis, Biogen, Roche, Bristol Myers Squibb, Almirall and has received research support from Roche, Biogen and Merck. Cordioli received personal compensation for advisory board and speaking for Merck Serono, Novartis, Almirall, Biogen and Roche. Di Filippo participated on advisory boards for and received research support, speaker/writing honoraria and funding for traveling from Bayer, Biogen Idec, Genzyme, Merck, Mylan, Novartis, Roche, Teva and Viatris Di Sapio received personal compensation for speaking and consulting by Biogen, Novartis and Genzyme and has been reimbursed by Merck, Biogen, Genzyme and Roche for attending several conferences. Docimo received grants from Roche, Novartis, Biogen, Merck, Viatris, Genzyme. Ferraro received travel grants and/or speaker/advisory board honoraria from Biogen, Roche, Novartis, TEVA, Sanofi Genzyme, Merck Serono. Immovilli reports personal fees from Roche, Biogen, Merck. Iodice received speaker honoraria and/or consultancy from Biogen, Teva, Genzyme, Merck, Almirall, Roche. Lanzillo received personal compensations for speaking or consultancy from Biogen, Teva, Genzyme, Merck, Mylan, Novartis and Roche. Laroni received personal compensations from Merck, Biogen, Novartis, Roche, Almirall. Patti received personal compensation for serving on advisory board Almirall, Bayer, Biogen, Bristol Meyers Squibb, Merck, Novartis, Roche and Sanofi; he further received unrestricted research grants by Biogen, Merck, Roche, FISM, University of Catania and Reload (onlus patients association). Ruscica received speaker and/or advisors board fee from Merck, Novartis, Biogen, Genzyme. Salvetti reports grants and personal fees from Biogen, Merck, Novartis, Roche, Sanofi, Teva, grants from Italian Multiple Sclerosis Foundation, grants from Sapienza University of Rome. Schiavetti received consulting fees from Hippocrates Research, NovaNeuro, Sakura Italia, ADL Farmaceutici, Associazione Commissione Difesa Vista Onlus. Signoriello received speaker honoraria and/or consultancy from Biogen, Teva, Genzyme, Merck, Novartis, Almirall, Roche. Sormani received consulting fees from Merck, Biogen, Novartis, Sanofi, Roche, Geneuro, GSK, Medday, Immunic. Ulivelli received consulting fees from Biogen, Novartis, Serono. Funding StatementFunding FISM [2021/Special-Multi/001]. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the regional ethics committee of Liguria and at a national level by the Italian Medicines Agency.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors